Position in MSLE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,754,235
New position
Shares Held
489,207
first reported quarter
Ownership
2.35%
of shares outstanding
% of Portfolio
0.48%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SPHERA FUNDS MANAGEMENT LTD. holds $324,179,213 across 61 Biotechnology names. MSLE ranks #42 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MLYS |
Mineralys Therapeutics, Inc.
|
1,339,971 | $36,299,814 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
245,246 | $18,211,967 | |
| 3 | RARE |
Ultragenyx Pharmaceutical Inc.
|
809,333 | $16,955,526 | |
| 4 | SNDX |
Syndax Pharmaceuticals Inc
|
724,563 | $16,925,791 | |
| 5 | COGT |
Cogent Biosciences, Inc.
|
416,340 | $16,024,926 | |
| 6 | FOLD |
AMICUS THERAPEUTICS, INC.
|
603,377 | $8,724,831 | |
| 7 | APLS |
Apellis Pharmaceuticals, Inc.
|
214,914 | $8,645,990 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
139,900 | $7,902,951 |
All Filings in MSLE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,754,235 | 489,207 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||